Lappe Mark's Form 4 filing
Inhibrx Biosciences, Inc. (INBX) · filed Sep 3, 2024
- Accession no.
- 0001739614-24-000037
- Filed
- Sep 3, 2024
- Trade date
- Aug 29-Sep 3, 2024
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions. Open-market purchases total $596.8K. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lappe MarkCIK 0001366074 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 29, 2024 | Common Stock | PPurchaseAcquired | +10,000 | $14.03F1 | +$140,300 | 135,000 | Indirect | |
| Aug 30, 2024 | Common Stock | PPurchaseAcquired | +10,000 | $14.02F3 | +$140,200 | 145,000 | Indirect | |
| Sep 3, 2024 | Common Stock | PPurchaseAcquired | +15,288 | $15.66F4 | +$239,410.08 | 160,288 | Indirect | |
| Sep 3, 2024 | Common Stock | PPurchaseAcquired | +4,712 | $16.31F5 | +$76,852.72 | 165,000 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The shares were purchased in multiple transactions at prices ranging from $13.9079 to $14.245, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
Referenced by the price of 1 transaction in Table I.
- F3
The shares were purchased in multiple transactions at prices ranging from $13.96 to $14.13, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
Referenced by the price of 1 transaction in Table I.
- F4
The shares were purchased in multiple transactions at prices ranging from $15.115 to $16.11, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
Referenced by the price of 1 transaction in Table I.
- F5
The shares were purchased in multiple transactions at prices ranging from $16.115 to $16.465, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
Referenced by the price of 1 transaction in Table I.